Across TCGA pan-cancer cohorts, DDR2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DDR2 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in brain lower grade glioma (LGG), where higher DDR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DDR2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
LGG, PRAD, and UVM are the cancer types where DDR2 Mutation most reproducibly stratifies survival.